U.S. Bancorp (USB)

U.S. Bancorp enters mid-November near the top of its trading range, with the stock at $60.75 after a 0.33% dip in the last session on volume 32.1% below its average. The stock has gained 27.68% over the past year and 11.51% over six months, and it sits above its 20-day, 50-day and 200-day averages. Analysts are broadly positive, with 16 of 24 rating the stock Buy, while the stock trades at a 29.9% discount to the sector median P/E.

The clearest support for the stock is its record of earnings. U.S. Bancorp has beaten the EPS estimate in all eight of its recent reports, and the latest, on October 15, 2026, came in at $1.34 against a $1.32 estimate, a beat of 1.52%. The shares rose 2.33% in the first session after that report. The July 16, 2026 report beat by 5.47% and the January 20, 2026 report by 5.88%. The beats have been small but consistent, which is what investors look for in a bank whose earnings move with rates and credit.

At a trailing P/E of 11.57, the stock trades at a 29.9% discount to the sector median P/E of 16.5, and its price-to-sales ratio of 3.41 is 10.3% below the sector median of 3.8. Trailing GAAP earnings of $5.27 per share support that multiple. The discount is the main reason the valuation factor scores so strongly, but a lower multiple also reflects slower revenue growth.

Of 24 analysts, 16 rate U.S. Bancorp Buy or Strong Buy, 8 rate it Hold, and none rate it Sell. Three months ago, 14 of 23 ratings were Buy. Recent actions were mixed in tone but none were downgrades: UBS and Oppenheimer both kept their ratings on November 2, 2026, JP Morgan kept its Neutral rating on October 30, 2026, and Citigroup and DA Davidson kept Buy ratings on October 16, 2026. Wolfe Research took over coverage at Peer Perform on October 27, 2026.

Insiders sold $22.4M of stock across 11 sales over the last 18 months and made no open-market purchases. Such sales are often planned in advance or made to cover tax on vesting shares, so they are a weaker signal than purchases would be, but the absence of buying is still worth noting for a reader weighing the stock against its rising price.

The base case is that U.S. Bancorp keeps its gains above the 20-day EMA and the 50-day and 200-day averages, with earnings growth carrying the valuation. Analysts expect EPS to rise 14.6% this year to an average of $5.29, then a further 10.7% next year to $5.86. Their range of 12-month targets runs from $65.00 to $75.00, so even the lowest target is above the current price, and the median target of $68.50 sits 12.8% above the price. The case weakens if the price loses the 20-day EMA at $59.71 and then the 50-day SMA at $59.60, which would suggest the trend is fading. A move above the 52-week high of $66.08 would be the stronger signal of further upside. Insider selling, with $22.4M of sales and no open-market purchases over the last 18 months, is a point to watch alongside those levels.

Support sits first at the 20-day EMA of $59.71, a short-term average the price is currently holding above. Below it, the 50-day SMA at $59.60 is nearly the same level and marks the medium-term trend line, so the two together form a shallow support band. The 200-day SMA at $58.23 is the longer-term trend line, and the 52-week low of $45.02 is the deepest floor on the chart. Resistance is the 52-week high of $66.08, the first level the price would meet on a rise and the top of its one-year range.